Ionis Pharmaceuticals Inc (IONS)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$38.80-3.36%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · IONS
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -46.6% |
| Our one-year growth estimate | diamond | 45.0% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 91.5 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-05 · Compared with 117 industry peers · Company calendar date is not available
IONS — CEO transition
Dated 2026-06-08
Director — Ludwig N. Hantson: Dr. Ludwig N. Hantson was appointed as a member of the Board of Directors.
Why it matters: Partner GSK's FDA approval gives bepirovirsen a path to reach patients with chronic hepatitis B. Sales reports can show early uptake.
Supportive ifGSK or Ionis reports HIBSAGO sales after launch in the approved patient group.
Worry ifThe next earnings report gives no HIBSAGO launch or sales update, or reports a launch delay.
Why it matters: Ionis raised its 2026 revenue range to $875–900 million. The next earnings report can show whether sales and partner payments support that goal.
Watch forIonis keeps its $875–900 million 2026 revenue range or raises it.
Also watch forIonis cuts its 2026 revenue range below $875 million.
Why it matters: The Phase 3 study met its week 37 proteinuria goal, but the trial continues. Week 105 eGFR results will test kidney function over time.
Watch forThe study reports a favorable week 105 change in eGFR versus placebo.
Also watch forThe study reports no week 105 eGFR benefit versus placebo, or worse kidney function.
Why it matters: FDA approval opened the way for Ionis's first independent launch in its neurology portfolio. Early sales can show whether that launch is gaining traction.
Supportive ifIonis reports ZANVASTRO sales and gives a launch update in its next earnings report.
Worry ifThe next earnings report gives no ZANVASTRO sales or reports a launch delay.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$201 on $10,000 · ±2.0% | How much price usually moves either way. |
| Bad day | $402 loss on $10,000 · 4.0% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $5,514 loss on $10,000 · 55.1% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.